Unfavorable early-stage Hodgkin lymphoma: assessment of patient characteristics in a real-world setting

Author:

Gautam Santosh1ORCID,Yeola Shweta1,Nahar Akash2,Sarpong Eric M2,Prescott Jennifer2,Yang Xiaoqin2,Sineshaw Helmneh M2

Affiliation:

1. ConcertAI, Cambridge, MA 02138, USA

2. Merck & Co., Inc., Rahway, NJ 07065, USA

Abstract

Aim: Unfavorable prognostic factors among classical Hodgkin lymphoma (cHL) patients in the real-world setting have yet to be fully characterized. Methods: In this retrospective study using the ConcertAI Oncology Dataset, patient characteristics, unfavorable prognostic factors and treatment patterns were evaluated among patients diagnosed with cHL. Results: Among 324 adult cHL patients diagnosed 2016–2021, 16.1% were classified as early favorable, 32.7% early unfavorable and 51.2% advanced disease. Early unfavorable patients were younger and had a larger nodal mass. The prognostic factor B symptoms was most frequently documented in early unfavorable patients (59.4%), followed by bulky disease (46.2%), >3 involved lymph node regions (31.1%), and erythrocyte sedimentation rate ≥50 (25.5%). Conclusion: In this analysis of real-world data, we found that nearly a third of newly diagnosed cHL patients had early unfavorable disease. Our analysis also showed differences in the proportion of patients for each unfavorable factor among patients with early-stage unfavorable cHL.

Funder

Merck

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Reference18 articles.

1. Cancer Statistics, 2021

2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: hodgkin lymphoma. https://seer.cancer.gov/statfacts/html/hodg.html (Accessed 18 June 2021).

3. 2016 US lymphoid malignancy statistics by World Health Organization subtypes

4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hodgkin Lymphoma V.2.2022. © National Comprehensive Cancer Network, Inc (2022). (All right reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way). https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-content (Accessed 23 February 2022).

5. Cheng J. Cotswolds-modified Ann Arbor classification | Radiology Reference Article | Radiopaedia.org. https://radiopaedia.org/articles/cotswolds-modified-ann-arbor-classification-2?lang=us

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3